The Joint Corp (JYNT)vsNovartis AG ADR (NVS)
JYNT
The Joint Corp
$8.37
+0.36%
HEALTHCARE · Cap: $119.03M
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 99997% more annual revenue ($56.69B vs $56.64M). NVS leads profitability with a 22.5% profit margin vs 5.7%. NVS appears more attractively valued with a PEG of 4.15. NVS earns a higher WallStSmart Score of 51/100 (C-).
JYNT
Hold47
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JYNT.
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.83
$66.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Earnings expanding 43.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
5.7% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JYNT
The strongest argument for JYNT centers on Return on Equity, Debt/Equity, EPS Growth. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : JYNT
The primary concerns for JYNT are Market Cap, Profit Margin, PEG Ratio. A P/E of 92.8x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
JYNT carries more volatility with a beta of 1.09 — expect wider price swings.
JYNT is growing revenue faster at 13.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 47/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?